The researchers further administered standard-dose (0.16 mg/kg/day) ATO monotherapy to a non-APL AML patient carrying an ATO-sensitive p53 mutation, observing the effective restoration of p53 transcriptional regulatory function accompanied by the significant clearance of minimal residual disease (MRD) [44]. The gene discussed is TP53; the disease is acute promyelocytic leukemia.